Flt3 Ligand Porcine

Flt3 Ligand (Flt3L) is a crucial growth factor involved in the regulation of hematopoiesis, the process by which blood cells are formed. It plays a significant role in the proliferation, differentiation, and survival of hematopoietic progenitor cells. The recombinant form of Flt3 Ligand, specifically derived from porcine sources, has been utilized in various research and therapeutic applications.

Flt3 Ligand Porcine Recombinant is produced in Escherichia coli (E. coli) and is a non-glycosylated polypeptide chain consisting of 155 amino acids. It has a molecular mass of approximately 17.3 kDa . The recombinant protein is purified using proprietary chromatographic techniques to ensure its purity and functionality.

Flt3 Ligand binds to the Flt3 receptor, a class III receptor tyrosine kinase, which is expressed on the surface of hematopoietic progenitor cells. This interaction triggers a cascade of signaling pathways that promote the survival, proliferation, and differentiation of these progenitor cells into various blood cell lineages, including dendritic cells, monocytes, and granulocytes .

The recombinant form of Flt3 Ligand has been extensively used in research to study the development and function of dendritic cells. Dendritic cells are key players in the immune system, acting as antigen-presenting cells that initiate and regulate immune responses. In vitro studies have shown that Flt3 Ligand can efficiently generate conventional dendritic cells (cDCs) from bone marrow hematopoietic cells .

Flt3 Ligand has potential therapeutic applications in enhancing immune responses, particularly in cancer immunotherapy. By promoting the development and activation of dendritic cells, Flt3 Ligand can enhance the body’s ability to recognize and attack cancer cells. Additionally, it may have applications in regenerative medicine by supporting the expansion of hematopoietic stem cells for transplantation purposes.